29 天前 - … real-world studies reporting PROMs on advanced therapies (including small
molecules and biologics) in moderate-to-severe UC patients. Studies published in English as full …

43 天前 - … the primary therapy with or without biologics for moderate to severe … diseases, such
as inflammatory bowel disease, is … and biologic therapy and had refractory disease course (…

61 天前 - … clinical remission by Crohn’s Disease Activity Index (CDAI) (p=0.113117). Although
superiority to uste in endoscopic response was not achieved (p=0.51), in biologic failed pts …

156 天前 - … This article is being published jointly in Inflammatory Bowel Diseases and
Gastroenterology. Crohn’s & Colitis Congress® as maintenance therapies in moderate-to-severe CD …

176 天前 - … are rare, comparative effectiveness and safety studies with … when positioning
biologic drugs in the treatment algorithm … -treated biologic-naïve patients with moderate-to-severe …

181 天前 - … ) with moderate-to-severe Crohn’s disease. Here we present primary efficacy and
safety of … The adjusted risk differences were calculated, and the comparison was performed by …

181 天前 - … demonstrate efficacy and safety of mirikizumab (miri), a p19-directed anti-IL-23
antibody, compared to placebo (PBO) in patients (pts) with moderate-to-severe Crohn’s disease. …

181 天前 - … along with rates of inflammatory bowel disease (IBD)-related … %) had received prior
biologic therapy, with approximately … of pts had moderate to severe disease (sPCDAI ≥30) …

181 天前 - Background ABP 654 is being developed as a biosimilar candidate to ustekinumab
reference product (RP), a biologic agent used in the treatment of certain chronic, immune-…

181 天前 - … comparable efficacy and safety with IV infliximab in ulcerative colitis (UC) or Crohn's
disease (… We aimed to investigate the one-year real-life efficacy and durability of IFX-SC in …